&nbsp;

Intent: Palliative

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) in combination with Chemotherapy - Metastatic Breast Cancer

New Drug Funding Program

Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer

Drugs Used:

PACLitaxel,

trastuzumab

Quick Link(s):

Regimen Monograph

May 2024

Patient Education Program

Regimen

PNAT

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria

Drugs Used:

ponatinib

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

PERTuzumab,

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

PAZO

Cancer Type:

Sarcoma,

Soft Tissue

Intent: Palliative

Drugs Used:

pazopanib (Unfunded)

Quick Link(s):

Regimen Monograph

Dec 2024

Plan pour la lutte contre le cancer en Ontario 2015-2019

Regimen

PIRT

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Drugs Used:

pirtobrutinib (Unfunded)